Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is […]
Read MoreJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique […]
Read MoreMarket conditions are Bullish in a Bull Market as of 2024-03-27. This means traders and investors should consider trading with a Bullish bias by buying (going long) stocks, long ETF’s or Call Options. The rank of the Bull Market is 21.62 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]
Read MoreMarket conditions are Bullish in a Bull Market as of 2024-03-26. This means traders and investors should consider trading with a Bullish bias by buying (going long) stocks, long ETF’s or Call Options. The rank of the Bull Market is 21.46 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]
Read MoreMarket conditions are Bullish in a Bull Market as of 2024-03-25. This means traders and investors should consider trading with a Bullish bias by buying (going long) stocks, long ETF’s or Call Options. The rank of the Bull Market is 21.33 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]
Read MoreMarket conditions are Bullish in a Bull Market as of 2024-03-22. This means traders and investors should consider trading with a Bullish bias by buying (going long) stocks, long ETF’s or Call Options. The rank of the Bull Market is 21.19 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]
Read MoreSera Prognostics, Inc. (SERA) Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. Spotify Technology S.A. (SPOT) Spotify Technology S.A., together with its subsidiaries, provides audio streaming subscription services worldwide. It operates through two segments, Premium and Ad-Supported. Kodiak Sciences Inc. (KOD) […]
Read MoreMind Medicine (MindMed) Inc. (MNMD) is a biotechnology company focused on the discovery, development, and deployment of psychedelic-inspired medicines and therapies to address mental health and neurological conditions. The company is primarily involved in clinical research and trials to explore the therapeutic potential of psychedelics like LSD, MDMA, psilocybin, and ibogaine in treating conditions such […]
Read MoreJanux Therapeutics Inc (JANX) is a biopharmaceutical company focused on developing innovative cancer immunotherapies. The company aims to harness the power of the immune system to target and eliminate cancer cells. Their approach involves creating novel therapeutics that can stimulate the body’s immune response against tumors, potentially leading to improved outcomes for patients with various […]
Read MoreSavara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Their lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Autoimmune PAP is a disease that belongs to a family of distinct, rare lung diseases collectively referred to as PAP. Autoimmune PAP […]
Read MoreIDEAYA Biosciences, Inc. (IDYA) IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Mereo BioPharma Group plc (MREO) Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United […]
Read MoreZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial […]
Read MoreBiohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company’s pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases.
Read MoreMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the […]
Read MoreSavara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim. An inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.
Read More